Introduction

Ca
2+ ions are involved in the regulation of a variety of cellular processes such as muscle contraction, secretion, proliferation or cell death (Ref. -binding proteins, ion pumps and ion exchangers (Refs. 2, 3, 4). This fine regulation of Ca 2+ homeostasis allows this ion to act as one of the most important second messengers in signal transduction.
In skeletal muscle fibres, the status of the excitation-contraction-relaxation cycle is determined by the cytosolic Ca 2+ levels: high 1 Ca 2+ levels are crucial for triggering muscle contraction, while low levels are critical for initiating muscle relaxation. Hence, a fast Ca 2+ -cycling mechanism and an efficient storage process are absolutely essential in muscle fibres. During normal contractions, local cytosolic Ca 2+ concentration is greatly increased reaching up to 20 μM (Refs. 5, 6). In addition to these Ca 2+ transients associated with muscle contraction, smaller but prolonged increases in intracellular Ca 2+ levels associated with long-duration fatigue have been described (Ref. 7). Additionally, small but persistent increases in basal intracellular Ca 2+ concentration likely occur during certain muscle diseases and in ageing (Ref. 8) . Since changes in cytosolic Ca 2+ levels are particularly frequent and diverse in the skeletal muscle, a tight control in Ca 2+ homeostasis is most significant in this system. In this regard, small changes in the Ca 2+ handling apparatus in the skeletal muscle might result in major pathophysiological consequences. Indeed, abnormal expression patterns of ionregulatory proteins have been reported repeatedly in muscular dystrophy (Refs. 9, 10, 11, 12, 13).
Existing evidence implicates Ca 2+ dysregulation as a common underlying event in the pathophysiology of muscular dystrophies, a group of diseases characterised by a primary degeneration of skeletal muscle tissue that results in progressive muscle weakness. This review examines Ca 2+ handling in muscular dystrophies, with a special focus on dystrophinopathies, calpainopathies and myotonic muscular dystrophies. We also summarise recent advances in our understanding of Ca 2+ ion cycling through the sarcolemma, the sarcoplasmic reticulum (SR) and mitochondria, and its involvement in the pathogenesis of these dystrophies. Finally, we discuss some of the clinical implications of these findings, and in particular, novel pharmacological therapeutic approaches for muscular dystrophies that target Ca 2+ regulatory proteins.
Calcium handling in the skeletal muscle Structure and physiology of the skeletal muscle
The skeletal muscle is under the control of the somatic nervous system through innervation of muscle fibres by motoneurons. Muscle fibres are long, cylindrical multinucleated cells that originate from the fusion of myoblasts during embryonic development and behave as a single unit. Each fibre contains several bundles of myofibrils, with inter-digitating myosin (thick) and actin (thin) filaments arranged longitudinally in repeating units known as sarcomeres. This particular arrangement of the cytoskeletal elements accounts for the banding pattern, characteristic of skeletal fibres. Actin filaments are bound to the Z line, which forms the borders of the sarcomere. At this location, deep invaginations of the sarcolemma (T-tubules) permit the conduction of the electrical impulses to the cell interior (Fig. 1) . A single motoneuron innervating one or more muscle fibres with similar functional properties constitutes a motor unit. A muscle is formed by many motor units, each one bringing its own specific contribution (Ref. 14). Motor units differ in the size of motoneurons and also in the type of innervated muscle fibres. They are divided into three categories: (a) slow; (b) fast fatigable; and (c) fast fatigue-resistant motor units (Ref. 15 
Calcium dysregulation in muscular dystrophies
In this section, we will discuss current knowledge 
Calpainopathies
LGMDs are a large group of hereditary muscular dystrophies characterised by progressive proximal weakness and a predominant involvement of the scapula, pelvic girdle and trunk muscles without affecting cardiac or facial muscles (Ref. 124) . Among the recessive forms of LGMDs, calpainopathy or LGMD2A is the most frequent muscular dystrophy with a prevalence of 82-100% in genetically isolated populations such as the Basque Country (Refs. 125, 126) .
LGMD2A is caused by mutations in the gene encoding Calpain 3 (CAPN3), a non-lysosomal cysteine protease necessary for normal muscle function and regeneration (Refs. 127, 128) . The exact pathogenic mechanisms that underlie muscular dystrophic features caused by mutations in CAPN3 are still unclear, and in view of the lack of effective therapies available for LGMD2A patients, understanding these pathological mechanisms is needed in order to advance in the design of potential treatments.
In skeletal muscle CAPN3 is present in different subcellular locations including myofibrils, membrane and cytoplasm. Most of the CAPN3 is bound within the contractile filament network, where it remains in its inactive state through its association with titin, a giant protein that connects the Z line to the M line in the sarcomere (Refs. 129, 130 Finally, there seems to be a connection between CAPN3 and mitochondrial function, since LGMD2A patients and CAPN3 knockout mice show abnormal distribution and structure of mitochondria in skeletal fibres (Ref. 141 ). Moreover, CAPN3-deficient muscles show ATP production deficits and increase oxidative stress levels (Ref. 142) . Accordingly, muscles with higher percentage of slow twitch fibres, which have higher oxidative metabolism, are the most affected in CAPN3 knockout mice (Refs. 21, 142). These mitochondrial abnormalities are likely associated to a severe Ca 2+ dysregulation in CAPN3-deficient muscle fibres, although future experiments are still needed in order to elucidate the pathogenic mechanisms involved in the mitochondrial dysfunction observed in LGMD2A.
Myotonic dystrophy
Myotonic dystrophy type 1 (DM1), the most frequent adult form of muscular dystrophy (Ref. 143) , is an inherited autosomal dominant disease caused by an unstable expansion of the CTG triplet repeat located in the 3 ′ untranslated region of DMPK gene that codes for myotonic dystrophy protein kinase. This gene is located in the long arm of chromosome 19 and it is predominantly expressed in skeletal muscle (Ref. 144) . DM2 form is a rare disease associated with a CCTG tetranucleotide repeat expansion, located in the first intron of the zinc finger protein 9 (ZNF9) gene in chromosome 3. Thus, both DM1 and DM2 originate from long noncoding repeat expansions, which cause a similar chronic, slowly progressing, multisystemic disease with a dominant inheritance pattern. Expanded mRNA molecules in the cell nucleus affect expression and/or re-allocation of RNAbinding proteins and lead to alteration in RNA processing (Refs. 145, 146, 147) . The multisystemic nature of both diseases is thought to be caused by aberrant splicing affecting a number of proteins involved in multiple cellular processes. It has recently been shown that myotonic dystrophy is associated with deregulated alternative splicing of the gene CACNA1S that encodes for DHPR alpha 1S subunit (DHPRα1s), a voltage sensor that plays a central role in E-C coupling (Ref. 148) . In DM1 and DM2, skipping of CACNA1S exon 29 is enhanced, which increases DHPRα1s channel conductance and voltage sensitivity. The longterm consequences are very likely harmful to muscle, especially when DHPR missplicing is combined with deregulated alternative splicing of other genes related to Ca 2+ -handling or E-C coupling such as the ones encoding chloride channel type 1, SERCA and RyR1 (Refs. 149, 150) . This would likely lead to a chronic Ca 2+ overload, a common scenario occurring in other forms of muscular dystrophies. In fact, several studies have reported that Ca 2+ -signalling pathways are consistently affected in DM muscles, DM myotubes and mouse models of this disease (Refs. 151, 152, 153) . These findings suggest that the combined effect of misregulated splicing of several genes involved in Ca 2+ regulation and E-C coupling contributes to muscle degeneration in myotonic dystrophy. In particular, a recent study performed on human DM samples demonstrates abnormal expression of mRNA and proteins involved in muscle Ca 2+ release, reuptake, storage and signalling, such as junctophilin-1 (JPH1), SERCA2, RyR1, CSQ2 and DHPR (Ref. 153) . In DM muscles they expert reviews http://www.expertreviews.org/ in molecular medicine found reduced protein levels of JPH1, but not mRNA, which is consistent with a general dysregulation of Ca 2+ homeostasis since JPH1 undergoes Ca 2+ -dependent proteolysis when intracellular Ca 2+ levels are elevated for a sustained period (Refs. 154, 155) . Interestingly, in most cases mRNA levels of Ca 2+ -handling molecules were found increased while the protein levels were decreased, which suggests that the translational block may be one of the underlying mechanisms of DM.
Therapeutic targeting of mitochondria and calcium homeostasis in muscular dystrophies
Over the years, several pharmacological and molecular therapies that target Ca 2+ homeostasis and/or mitochondrial function have been proposed as potential treatments for muscular dystrophies (summarised in Table 2 ). Different studies have demonstrated beneficial effects of RyR stabilisers on different animal models of muscular dystrophy and heart failure (Refs. 50, 101, 156) . In particular, treatment of mouse models of Duchenne and LGMD2E muscular dystrophy with the RyR stabiliser S107 results in reduced RyR1 nitrosylation, reversion of calstabin-1 depletion and an overall improvement of muscle function and exercise performance (Refs. 101, 156) . Interestingly, a recent study has demonstrated that S107, as well as the RyR inhibitor dantrolene, synergise with antisensemediated exon-skipping therapies and increases muscle function in mdx mice and human DMD myotubes (Ref. 157) . Also, several Ca 2+ channel blockers such as nifedipine, diltiazem and verapamil have shown to improve muscle structure and function in dystrophic mice (Refs. 158, 159), but they have failed to prove significant beneficial effects on DMD patients in clinical trials (Ref. 160 ). Likewise, pharmacological or molecular blockage of stretch-activated channels (TRPC, TRPV2) has also shown a beneficial effect on several dystrophic models (Refs. 89, 161) .
Angiotensin II-receptor blockers, β-blockers and angiotensin-converting-enzyme inhibitors have shown beneficial effects for the treatment of cardiomyopathies in clinical trials and animal models (Refs. 162, 163 Features associated with this article Figure  Figure 1 . Representation of calcium signalling dynamics in the muscle fibre. Tables  Table 1. Calcium-related mechanisms affected in muscular dystrophies. 
